{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:16:40Z","timestamp":1762957000767,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["ARP-2852","ARP-8129","R01AI147330","pNL4-3"],"award-info":[{"award-number":["ARP-2852","ARP-8129","R01AI147330","pNL4-3"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["HB1 164063"],"award-info":[{"award-number":["HB1 164063"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jgar.2022.11.001","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T12:36:11Z","timestamp":1667651771000},"page":"323-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report"],"prefix":"10.1016","volume":"31","author":[{"given":"Jeroen J.A.","family":"van Kampen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanh Thi","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunbin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Overmars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-9628","authenticated-orcid":false,"given":"Cynthia","family":"Lungu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina A.M.","family":"Schurink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-3313","authenticated-orcid":false,"given":"Sander","family":"van Boheemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-5903","authenticated-orcid":false,"given":"Rob A.","family":"Gruters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter L.A.","family":"Fraaij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-2818","authenticated-orcid":false,"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda J.C.","family":"Voermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1904-6450","authenticated-orcid":false,"given":"Casper","family":"Rokx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8526","authenticated-orcid":false,"given":"David A.M.C.","family":"van de Vijver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0515-9128","authenticated-orcid":false,"given":"Thibault","family":"Mespl\u00e8de","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.11.001_bib0001","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2022.11.001_bib0002","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3018(20)30231-9","article-title":"End resistance to dolutegravir roll-out","volume":"7","author":"The Lancet H","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2022.11.001_bib0003","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/14656566.2018.1560423","article-title":"Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications","volume":"20","author":"Pham","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2022.11.001_bib0004","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.11.001_bib0005","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/infdis\/jiy176","article-title":"HIV-1 resistance dynamics in patients with virologic failure to dolutegravir maintenance monotherapy","volume":"218","author":"Wijting","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.001_bib0006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2018.12.008","article-title":"Development and validation of an UPLC-MS\/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma","volume":"1105","author":"Bollen","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jgar.2022.11.001_bib0007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkaa471","article-title":"Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir","volume":"76","author":"Pham","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.11.001_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mesplede","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.jgar.2022.11.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104717","article-title":"Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient","volume":"179","author":"Lozano","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jgar.2022.11.001_bib0010","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1056\/NEJMc1806554","article-title":"Failure of dolutegravir first-line ART with selection of virus carrying R263K and G118R","volume":"381","author":"Lubke","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.11.001_bib0011","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11904-021-00568-9","article-title":"A review of interventions to enhance HIV medication adherence","volume":"18","author":"Whiteley","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.jgar.2022.11.001_bib0012","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jgar.2022.11.001_bib0013","doi-asserted-by":"crossref","first-page":"ofz330","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in HIV treatment-experienced patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.001_bib0014","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of pre-existing NRTI resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients: real-world data","volume":"36","author":"Mican","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.11.001_bib0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/v12111330","article-title":"Emergence of resistance to integrase strand transfer inhibitors during dolutegravir containing triple-therapy in a treatment-experienced patient with pre-existing M184V\/I mutation","volume":"12","author":"Braun","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2022.11.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106039","article-title":"Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure","volume":"56","author":"Andre-Garnier","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.11.001_bib0017","doi-asserted-by":"crossref","first-page":"ofab297","DOI":"10.1093\/ofid\/ofab297","article-title":"Case report: emergent resistance in a treatment-naive person with Human Immunodeficiency Virus under bictegravir-based therapy","volume":"8","author":"Chamberlain","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.001_bib0018","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522002478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522002478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:49Z","timestamp":1761991309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522002478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":18,"alternative-id":["S2213716522002478"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.11.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}